Oxford Events, the new replacement for OxTalks, will launch on 16th March. The two-week OxTalks freeze period starts on Monday 2nd March. During this time, there will be no facility to publish or edit events. The existing OxTalks site will remain available to view during this period. Once Oxford Events launches, you will need a Halo login to submit events. Full details are available on the Staff Gateway.
Intracerebral haemorrhage (bleeding in the brain), also known as haemorrhagic stroke, leads to approximately 3 million deaths worldwide per year and leaves many survivors disabled and dependent on others. It is possible that administering medications to stop bleeding quickly after the onset of intracerebral haemorrhage might reduce the risk of people dying or becoming disabled. This talk will outline pre-clinical work assessing the role of Von Willebrand factor for reversing or reducing the effects of antiplatelet drugs (these are prescribed in patients who are at risk of heart attacks or blood clots, but they increase the risks from intracerebral haemorrhage) and discuss ongoing clinical trials of tranexamic acid and desmopressin aimed at reducing bleeding. It will also discuss research into newborn babies with a condition called Fetal and Neonatal AlloImmune Thrombocytopenia (FNAIT), who are at risk of intracerebral haemorrhage in the womb or shortly after birth.
